about
The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathologyAssociation between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implicationsSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceAmygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia.A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?A systematic review of the effects of antipsychotic drugs on brain volume.Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.Role of the central cholinergic system in the therapeutics of schizophrenia.Spreading of complex regional pain syndrome: not a random process.Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis.Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives.A pathophysiological paradigm for the therapy of psychiatric disease.Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study.Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review.Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence.Postmortem studies in schizophrenia.Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (±)-α-lipoic acid in SH-SY5Y neuroblastoma cells.Changes in brain functional connectivity after chronic haloperidol in rats: a network analysis.α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia.Neuropathological changes in the nucleus basalis in schizophrenia.Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia.Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment.Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia.Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development.Effects of Hallucinogens on Neuronal Activity.Mitochondria in the striatum of subjects with schizophrenia.NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations
P2860
Q28212819-91E826B4-09CA-479E-9758-BC9393F3F54FQ28298135-58A0DAF8-C588-4F79-A756-87EC768B92E0Q29618819-947201B1-E15F-4283-A65A-C3481A2B387AQ31912055-C7C47358-2C5A-4E19-B263-D4BA64652305Q33284843-F1B9FA83-B054-4D7A-B6FA-DD4C26582737Q33525203-BD252797-A452-4616-8EF5-F943326A3E89Q34224434-58D764BC-A0D7-4B01-B6A5-A15AD7ED6BF6Q34274859-E9EF78F8-EA29-4B92-B2B6-1032E9B0373CQ34383654-40337891-88E7-4B1C-AA9E-2A4C20249F97Q34608625-EA7168DC-50F2-43B8-AA6F-B42F5A8B67E3Q35182187-492F643C-AB99-4415-B841-068DE629B587Q35550905-CA6058E7-28EE-40B3-A6A2-CDC3B57EBA3BQ35579200-CFEFB8DD-5D10-49A1-A200-D3460D6CEF55Q36148434-CFFA4BBB-8D65-4126-9CA3-92692D7F8481Q37478385-73609B2E-AF2C-4A3E-8091-F7FB3135B211Q37920918-60F3CE80-0D2A-4B5F-86DE-EC099269782CQ38244017-DB4373A1-0B0A-4963-A3F0-5F745CA95407Q38578521-B7D74ED8-FB27-4280-9939-AA83A65A8A18Q39066006-0153B3F8-F732-4A2F-9FCB-ECD7E77CD0E0Q39251232-D9578357-FE6B-4385-B277-85E2783C46E0Q39279185-B94FAD73-D8F4-4881-930D-FC5EA7F85CABQ39998926-04E729C9-27D7-4790-864C-1DD0663BB45EQ42517769-DA6392DB-106B-4F1D-8EA1-7157B30AE22EQ43040891-6B49E5C7-A24C-4692-BDB8-6A1518100547Q44060448-AF73D469-98F4-4AF5-BD26-E4B48288BEEDQ44971614-E111B83D-2CCF-47B2-B578-90CE30F0C5A5Q47673850-A5935036-DB3D-4EAF-87B0-36DC890C209CQ47791105-7CF68A73-0183-4F84-8C42-D518B1D0C299Q48094326-33791AC2-25A1-42CF-9F77-78432976C628Q57016043-6EE4445D-6CC5-4A86-AB13-8CC92AFD6C74
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The neuropathological effects of antipsychotic drugs.
@ast
The neuropathological effects of antipsychotic drugs.
@en
type
label
The neuropathological effects of antipsychotic drugs.
@ast
The neuropathological effects of antipsychotic drugs.
@en
prefLabel
The neuropathological effects of antipsychotic drugs.
@ast
The neuropathological effects of antipsychotic drugs.
@en
P1476
The neuropathological effects of antipsychotic drugs.
@en
P2093
P J Harrison
P356
10.1016/S0920-9964(99)00065-1
P407
P577
1999-11-01T00:00:00Z